SCHEMBL260265

SCHEMBL260265

Cn1cc(CN2CCOCC2)cc1C=O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.49
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NCF1 P14598 1/20 0.41
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
KCNJ1 P48048 1/20 0.39
BRD4 O60885 1/20 0.38
CCL2 P13500 1/20 0.38
NOS1 P29475 2/20 0.38
ERN1 O75460 1/20 0.38
POLB P06746 1/20 0.38
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260477 0.71 HRH3 (0.41) HRH3SMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL5604785 0.70 HRH3 (0.51) HRH3MAPTSMN1; SMN2NCF1ALDH1A1
SCHEMBL207661 0.69 HRH3 (0.65) HRH3MAPTSMN1; SMN2HTTALDH1A1
SCHEMBL31528286 0.69 NCF1 (0.62) HRH3SMN1; SMN2NCF1HTTKDM4E
SCHEMBL208910 0.69 NCF1 (0.62) HRH3SMN1; SMN2NCF1HTTKDM4E
Butane SCHEMBL8486919 0.68 HRH3 (0.57) HRH3MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL259925 0.68 HRH3 (0.45) HRH3MAPTSMN1; SMN2NCF1HTT
SCHEMBL24492803 0.67 HRH3 (0.56) HRH3MAPTSMN1; SMN2NCF1HTT
SCHEMBL14058774 0.67 HRH3 (0.67) HRH3MAPTSMN1; SMN2HTTALDH1A1
SCHEMBL19869673 0.67 HRH3 (0.59) HRH3BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101987848-B New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing the same SERVIER LAB 2014-06-18 CN disclosed
US-8653073-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2014-02-18 US disclosed
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2013-12-12 US disclosed
US-8541412-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2013-09-24 US disclosed
EP-2281822-B1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB (FR) 2013-01-16 EP disclosed
US-8133889-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-03-13 US disclosed
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-02-23 US disclosed
CN-101987848-A New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB 2011-03-23 CN disclosed
WO-2011015728-A1 NOVEL DIHYDROINDOLONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2011-02-10 WO disclosed
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-02-10 US disclosed
EP-2281822-A1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2011-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CYP11B1, SDHA, CYP11B2 HRH3 922/4885MAPT 4278/4885SMN1; SMN2 2931/4885
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 HRH3 922/4885MAPT 4278/4885SMN1; SMN2 2931/4885
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 HRH3 922/4885MAPT 4278/4885SMN1; SMN2 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.